Developer docs
API playgroundTry for free, no card

Search company profiles

Genovac

Full company profile

uuid000blbq

Namestring
Genovac
Legal namestring
Genovac Antibody Discovery, LLC
Websiteurl
genovac.com
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Genovac Antibody Discovery is a privately held contract research and manufacturing organization (CRO/CMO) that provides integrated antibody discovery, production, and characterization services to biopharmaceutical, biotechnology, diagnostic, and academic customers across North America, Europe, Australia, and Asia. The company was originally founded in 1999 by three University of Freiburg professors in Germany and operated for a period as part of Aldevron before a 2020 management-led buyout relaunched it as an independent entity with US headquarters at the North Dakota State University Research & Technology Park in Fargo, ND, and a European scientific and production facility in Freiburg, Germany.

Genovac's core technical stack combines proprietary genetic immunization (which enables antibody generation directly from DNA without purified antigen) with multiple single B cell screening platforms — Berkeley Lights Beacon optofluidic systems (three instruments), the proprietary Genovac Nano bead-based platform, and 10X Genomics ChromiumX — plus advanced hybridoma workflows across diverse host species (mouse, rat, rabbit, llama, alpaca, and human PBMCs). Downstream capabilities include HEK and CHO antibody production, Carterra LSA HT-SPR and Gator Bio BLI characterization, functional assays, antibody sequencing, and a 2024-launched AI-based humanization service (GenovacAI) powered by ENPICOM's AIGX generative deep learning model. Catalog antibodies and an online plasmid DNA store (plasmidusa.com) provide additional transactional revenue.

The business model is primarily fee-for-service project-based contract research, with quote-based pricing, complemented by milestone- and royalty-based licensing income (notably an exclusive worldwide agreement with Pfizer announced in September 2023 for therapeutic antibody candidates). GTM is sales-led with consultative selling, complimentary target analysis, dedicated regional sales contacts for the US/Canada and Europe, conference presence (Festival of Biologics, Antibody Engineering & Therapeutics), and co-marketed webinars with technology partners. The company has completed more than 3,600 antibody discovery projects since 1999 and counts major pharma clients including Pfizer, Eli Lilly, and AbCellera among its enterprise users.

Short descriptiontext

Genovac is a private CRO/CMO offering integrated antibody discovery, production, and characterization services — built on genetic immunization and single B cell platforms — to biopharma, biotech, diagnostic, and academic clients across four continents.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersFargo, United States
HQ citystring
Fargo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody discovery services, contract research organization, single B cell screening, therapeutic antibody development, hybridoma technology
Industry1 code
PRIMARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Antibody Discovery Contract Research Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Contract Research Services
TypeProfessional Services
Description

Genovac provides fee-for-service antibody discovery, production, and characterization services to biotech and pharmaceutical companies. Projects are scoped individually with quotes and proposals, generating revenue through project-based fees.

genovac.com
2Catalog Antibodies
TypeOne Time License
Description

Sale of pre-made catalog antibodies for research use. Products include antibodies against various targets (IL-13R, IL17RB, Granzyme K, CEACAM family, etc.) sold at standard quantities (100ug).

genovac.com
3Plasmid DNA Production
TypeOne Time License
Description

Online store sales of plasmid DNA preps at various scales (Maxi, Mega, Giga, High-Throughput Mini/Midi) and custom orders. Revenue from product sales at different quality levels.

genovac.com
4Licensing and Royalties
TypeLicensing Royalties
Description

Exclusive licensing agreements with pharmaceutical companies for therapeutic antibody candidates. Receives upfront payments, milestone payments, and royalties on net sales of commercial products.

genovac.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Pricing details3 tiers
1Catalog Antibodies - 100ug standard quantity
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Standard catalog antibody products sold at 100 microgram quantity with price per unit

genovac.com
2Plasmid DNA Standard Preps - Scale-based pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Maxi (up to 1.5mg), Mega (up to 5mg), Giga (up to 10mg), High-Throughput Mini (sets of 48/96, up to 20ug), High-Throughput Midi (sets of 24-96, up to 250ug)

genovac.com
3Plasmid DNA Custom Preps - 1-100mg range
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Custom preps include Stable High Copy and Unstable Low Copy options with quantity range 1-100mg

genovac.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Genovac is a contract research organization that provides antibody discovery, production, and characterization services to biotech and pharmaceutical companies. The core offering spans a gene-to-antibody workflow using genetic immunization, single B cell screening platforms (Beacon, Genovac Nano, ChromiumX), advanced hybridoma technologies, antibody production in HEK/CHO hosts, AI-powered humanization, and high-throughput binding characterization via Carterra LSA. The company also sells catalog antibodies and operates an online plasmid DNA storefront.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 100x faster antibody characterization with 99% less sample using Carterra LSA
+3 more records
Product overview1 text field

Genovac is a contract research and manufacturing organization (CRO/CMO) offering integrated antibody discovery and production services. The core offerings include genetic immunization, advanced hybridoma, and single B cell screening platforms (Beacon, Genovac Nano, ChromiumX) for antibody discovery against challenging targets like GPCRs and ion channels. These core discovery technologies feed into integrated production and characterization services including high-throughput and scale-up antibody production in HEK/CHO cells, binding kinetics and epitope binning using Carterra LSA HT-SPR and Gator Bio BLI instruments, and functional assays. Additional services include AI-powered humanization (GenovacAI), antibody sequencing, recombinant protein production, and plasmid DNA manufacturing. Genovac also offers catalog antibodies and an online plasmid store. The portfolio spans from gene to antibody, providing clients with a comprehensive one-stop-shop solution for biologics development.

Product and service13 records
1Immunization Strategies
CategoryCore Discovery Technology
Description

Genetic immunization technology enabling development of antibodies against any protein target directly from DNA, electronic sequence, or accession number. Includes proprietary screening vectors for identification of positive antisera, single B cells, and hybridomas without purified antigen.

2Single B Cell Platforms
CategoryCore Discovery Technology
Description

Multiple automated single B cell antibody discovery platforms including Bruker's Beacon Optofluidic system, Genovac Nano bead-based screening, and 10X Genomics ChromiumX with NGS for rare antibody discovery.

3Advanced Hybridoma
CategoryCore Discovery Technology
Description

Highly efficient semi-solid and well-based fusion options for rapid delivery of antibodies comparable to yields of manual single B cell platforms, compatible with wild type and transgenic species.

4Multi-Species Host Options
CategoryDiscovery Service Component
Description

Multiple wild type and human-Ig transgenic species including mouse, rat, rabbit, llama, alpaca, and human PBMC for generating superior human therapeutic antibody candidates.

5GenovacAI Humanization
CategoryAI-Powered Service
Description

AI-based humanization service using generative deep learning algorithms (AIGX model) to humanize antibodies with high success rates. Enables humanization-forward engineering of multiple candidate antibodies post-discovery.

6Antibody Sequencing
CategoryDiscovery Service Component
Description

In-house hybridoma and single B cell antibody sequencing using Sanger and NGS techniques, including sequence analysis through ENPICOM software for phylogenetic analysis and CDR3 identification.

7Antibody Production
CategoryProduction Service
Description

High-quality antibody production services from small-scale high-throughput parallel production (up to 96 antibodies per batch) through scale-up production (1.4-20L culture volumes) in HEK or CHO hosts.

8Antibody Characterization
CategoryCharacterization Service
Description

Binding kinetics and epitope binning services using Carterra LSA HT-SPR platform (up to 384 antibodies for kinetics, 192x192 array for binning) and Gator Bio Gator Plus BLI (up to 24 antibodies).

9Antibody Functional Assays
CategoryCharacterization Service
Description

Functional characterization services including binding, cross reactivity, blocking, internalization, neutralization, and cytotoxicity assays using Incucyte, SpectraMax, Attune Flow Cytometers, and iQue platforms.

10Plasmid DNA Production
CategoryProduction Service
Description

Plasmid DNA production at microgram to gram scale with research grade and enhanced research grade quality levels, including process development and full quality testing suite.

11Recombinant Protein Production
CategoryProduction Service
Description

Flexible recombinant protein production from small-scale parallel to multi-gram scale in E. coli, HEK-293, and CHO cells with comprehensive purification and analytics.

12Catalog Antibodies
CategoryCatalog Product
Description

Pre-generated catalog antibodies against various human targets including IL-13R, IL17RB, Granzyme K, ICOSL, FASL, CEACAM family, CCR4, LGR4/5, CD34, EphA2, VEGFR2, and others for research use.

13Plasmid Store (plasmidusa.com)
CategoryE-commerce Platform
Description

Online ordering platform for standard and custom plasmid DNA preps including Maxi, Mega, Giga, and High-Throughput options at various purity and quantity levels.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-09-19
Description

Exclusive worldwide licensing agreement for therapeutic antibody candidates generated by Genovac in collaboration with a leading research university. Genovac receives upfront payment, development and commercial milestone payments, plus royalties on net sales of commercial products.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-03-13
Description

Public-private research collaboration focused on discovering high-quality antibodies against RAGE receptor for therapeutic development targeting melanoma and pancreatic cancer. NDSU researchers perform preclinical evaluation while Genovac provides discovery and production capabilities.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-05-02
Description

Genovac uses ENPICOM's IGX Platform for advanced data management and computational analysis in antibody discovery workflows. The partnership also includes joint development of GenovacAI Humanization service powered by ENPICOM's AIGX generative deep learning model.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-04-20
Description

Genovac acquired Carterra's LSA platform, a high-throughput antibody screening and characterization technology. The LSA platform uses high-throughput surface plasmon resonance (HT-SPR) technology and is the standard in 16 of the 20 largest pharmaceutical companies. The platform was used in discovery of COVID-19 therapeutics including bamlanivimab.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-10-05
Description

Partnership for Beacon Optofluidic System for single-cell screening. Genovac operates three Beacon instruments and became the first CRO to leverage the technology for both antibody discovery and cell line development. The technology enables screening of up to 160,000 B cells per project and has dramatically improved success rates on challenging targets.

Strategic tierSupportingTypeTechnology or Integration
Description

Genovac offers single B cell services using 10X Genomics Chromium X instrument combined with NGS sequencing for high-throughput screening of up to 240,000 cells per day with full-length V(D)J sequences.

Strategic tierSupportingTypeTechnology or Integration
Description

Partnership for Gator Plus biolayer interferometry (BLI) platform for binding kinetics and epitope binning as a cost-effective option for smaller antibody sets (up to 24 antibodies for kinetics, 12x12 arrays for binning).

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Public antibody discovery CRO combining single B cell screening, AI/ML, and a technology stack similar to Genovac's Beacon-based workflow. Closest publicly traded peer in business model and target customer base.

TypeDirect peer
Description

Private antibody discovery platform CRO serving pharma and biotech with proprietary yeast-based discovery. Direct competitor for outsourced antibody discovery programs targeting challenging proteins.

TypeDirect peer
Description

Transgenic-animal-based antibody discovery CRO offering humanized antibody generation from OmniAb platform animals. Closest direct peer to Genovac's transgenic host species (mouse, rat, rabbit, llama) offering.

TypeDirect peer
Description

Antibody discovery and development CRO, now part of Curia, offering hybridoma, B cell cloning, and characterization services that directly overlap Genovac's discovery-to-production pipeline.

5Distributed Bio (Charles River Laboratories)
TypeDirect peer
Description

Antibody discovery CRO (now part of Charles River) with SuperHuman and AbGenesis platforms; competes head-to-head with Genovac for therapeutic antibody discovery programs at biotech and pharma clients.

TypeDirect peer
Description

Biologics CDMO offering antibody discovery, cell line development, and GMP manufacturing. Comparable end-to-end biologics service portfolio with greater scale and global footprint.

7Absolute Antibody
TypeDirect peer
Description

Specialized antibody services company offering antibody sequencing, engineering, and recombinant production. Comparable in catalog and recombinant antibody services to Genovac's catalog and production offerings.

TypeBroad incumbent
Description

Global CDMO leader in biologics manufacturing with growing discovery services. Larger, established player with integrated discovery-through-GMP offering that competes with Genovac at the high end of the market.

TypeBroad incumbent
Description

Largest pure-play biologics CDMO globally with integrated antibody discovery through commercial manufacturing. Sets pricing and scale benchmarks against which specialized discovery CROs like Genovac must compete.

TypeBroad incumbent
Description

Major CDMO offering biologics development and manufacturing with GPEx cell line platforms. Notable as the prior employer of Genovac's VP Pete Leland and a comparable end-to-end biologics service provider.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Genovac

Antibody Discovery Contract Research Servicesgenovac.com

Genovac is a private CRO/CMO offering integrated antibody discovery, production, and characterization services — built on genetic immunization and single B cell platforms — to biopharma, biotech, diagnostic, and academic clients across four continents.

What Genovac does

Genovac Antibody Discovery is a privately held contract research and manufacturing organization (CRO/CMO) that provides integrated antibody discovery, production, and characterization services to biopharmaceutical, biotechnology, diagnostic, and academic customers across North America, Europe, Australia, and Asia. The company was originally founded in 1999 by three University of Freiburg professors in Germany and operated for a period as part of Aldevron before a 2020 management-led buyout relaunched it as an independent entity with US headquarters at the North Dakota State University Research & Technology Park in Fargo, ND, and a European scientific and production facility in Freiburg, Germany.

Genovac's core technical stack combines proprietary genetic immunization (which enables antibody generation directly from DNA without purified antigen) with multiple single B cell screening platforms — Berkeley Lights Beacon optofluidic systems (three instruments), the proprietary Genovac Nano bead-based platform, and 10X Genomics ChromiumX — plus advanced hybridoma workflows across diverse host species (mouse, rat, rabbit, llama, alpaca, and human PBMCs). Downstream capabilities include HEK and CHO antibody production, Carterra LSA HT-SPR and Gator Bio BLI characterization, functional assays, antibody sequencing, and a 2024-launched AI-based humanization service (GenovacAI) powered by ENPICOM's AIGX generative deep learning model. Catalog antibodies and an online plasmid DNA store (plasmidusa.com) provide additional transactional revenue.

The business model is primarily fee-for-service project-based contract research, with quote-based pricing, complemented by milestone- and royalty-based licensing income (notably an exclusive worldwide agreement with Pfizer announced in September 2023 for therapeutic antibody candidates). GTM is sales-led with consultative selling, complimentary target analysis, dedicated regional sales contacts for the US/Canada and Europe, conference presence (Festival of Biologics, Antibody Engineering & Therapeutics), and co-marketed webinars with technology partners. The company has completed more than 3,600 antibody discovery projects since 1999 and counts major pharma clients including Pfizer, Eli Lilly, and AbCellera among its enterprise users.

Genovac firmographics

Firmographics
Name
Genovac
Legal name
Genovac Antibody Discovery, LLC
Website
https://genovac.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
11–50 employees
Short description
Genovac is a private CRO/CMO offering integrated antibody discovery, production, and characterization services — built on genetic immunization and single B cell platforms — to biopharma, biotech, diagnostic, and academic clients across four continents.
Ownership category
akta.pro rank

Genovac industry classification

Industry
Product category
Antibody Discovery Contract Research Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (6215)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Antibody discovery services
  • Contract research organization
  • Single B cell screening
  • Therapeutic antibody development
  • Hybridoma technology

Where Genovac is headquartered

Location

Headquarters

HQ city
Fargo
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Genovac business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. Contract Research Services: Genovac provides fee-for-service antibody discovery, production, and characterization services to biotech and pharmaceutical companies. Projects are scoped individually with quotes and proposals, generating revenue through project-based fees.
  2. Catalog Antibodies: Sale of pre-made catalog antibodies for research use. Products include antibodies against various targets (IL-13R, IL17RB, Granzyme K, CEACAM family, etc.) sold at standard quantities (100ug).
  3. Plasmid DNA Production: Online store sales of plasmid DNA preps at various scales (Maxi, Mega, Giga, High-Throughput Mini/Midi) and custom orders. Revenue from product sales at different quality levels.
  4. Licensing and Royalties: Exclusive licensing agreements with pharmaceutical companies for therapeutic antibody candidates. Receives upfront payments, milestone payments, and royalties on net sales of commercial products.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goCatalog Antibodies - 100ug standard quantity
Unit PricingPay-as-you-goPlasmid DNA Standard Preps - Scale-based pricing
Unit PricingPay-as-you-goPlasmid DNA Custom Preps - 1-100mg range

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Genovac product offering

Product offering

Core offering

Genovac is a contract research organization that provides antibody discovery, production, and characterization services to biotech and pharmaceutical companies. The core offering spans a gene-to-antibody workflow using genetic immunization, single B cell screening platforms (Beacon, Genovac Nano, ChromiumX), advanced hybridoma technologies, antibody production in HEK/CHO hosts, AI-powered humanization, and high-throughput binding characterization via Carterra LSA. The company also sells catalog antibodies and operates an online plasmid DNA storefront.

Product overview

Genovac is a contract research and manufacturing organization (CRO/CMO) offering integrated antibody discovery and production services. The core offerings include genetic immunization, advanced hybridoma, and single B cell screening platforms (Beacon, Genovac Nano, ChromiumX) for antibody discovery against challenging targets like GPCRs and ion channels. These core discovery technologies feed into integrated production and characterization services including high-throughput and scale-up antibody production in HEK/CHO cells, binding kinetics and epitope binning using Carterra LSA HT-SPR and Gator Bio BLI instruments, and functional assays. Additional services include AI-powered humanization (GenovacAI), antibody sequencing, recombinant protein production, and plasmid DNA manufacturing. Genovac also offers catalog antibodies and an online plasmid store. The portfolio spans from gene to antibody, providing clients with a comprehensive one-stop-shop solution for biologics development.

Differentiator

Problem solved

Functional benefit

Products and services

  • Immunization Strategies Genetic immunization technology enabling development of antibodies against any protein target directly from DNA, electronic sequence, or accession number. Includes proprietary screening vectors for identification of positive antisera, single B cells, and hybridomas without purified antigen.
  • Single B Cell Platforms Multiple automated single B cell antibody discovery platforms including Bruker's Beacon Optofluidic system, Genovac Nano bead-based screening, and 10X Genomics ChromiumX with NGS for rare antibody discovery.
  • Advanced Hybridoma Highly efficient semi-solid and well-based fusion options for rapid delivery of antibodies comparable to yields of manual single B cell platforms, compatible with wild type and transgenic species.
  • Multi-Species Host Options Multiple wild type and human-Ig transgenic species including mouse, rat, rabbit, llama, alpaca, and human PBMC for generating superior human therapeutic antibody candidates.
  • GenovacAI Humanization AI-based humanization service using generative deep learning algorithms (AIGX model) to humanize antibodies with high success rates. Enables humanization-forward engineering of multiple candidate antibodies post-discovery.
  • Antibody Sequencing In-house hybridoma and single B cell antibody sequencing using Sanger and NGS techniques, including sequence analysis through ENPICOM software for phylogenetic analysis and CDR3 identification.
  • Antibody Production High-quality antibody production services from small-scale high-throughput parallel production (up to 96 antibodies per batch) through scale-up production (1.4-20L culture volumes) in HEK or CHO hosts.
  • Antibody Characterization Binding kinetics and epitope binning services using Carterra LSA HT-SPR platform (up to 384 antibodies for kinetics, 192x192 array for binning) and Gator Bio Gator Plus BLI (up to 24 antibodies).
  • Antibody Functional Assays Functional characterization services including binding, cross reactivity, blocking, internalization, neutralization, and cytotoxicity assays using Incucyte, SpectraMax, Attune Flow Cytometers, and iQue platforms.
  • Plasmid DNA Production Plasmid DNA production at microgram to gram scale with research grade and enhanced research grade quality levels, including process development and full quality testing suite.
  • Recombinant Protein Production Flexible recombinant protein production from small-scale parallel to multi-gram scale in E. coli, HEK-293, and CHO cells with comprehensive purification and analytics.
  • Catalog Antibodies Pre-generated catalog antibodies against various human targets including IL-13R, IL17RB, Granzyme K, ICOSL, FASL, CEACAM family, CCR4, LGR4/5, CD34, EphA2, VEGFR2, and others for research use.
  • Plasmid Store (plasmidusa.com) Online ordering platform for standard and custom plasmid DNA preps including Maxi, Mega, Giga, and High-Throughput options at various purity and quantity levels.

Quantifiable outcome

  • 100x faster antibody characterization with 99% less sample using Carterra LSA
  • +3 more outcomes

Companies that use Genovac

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Genovac technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

Genovac partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered flagship, core and supporting.

  • PfizerflagshipStrategic or Co-development Partner · 19 September 2023Exclusive worldwide licensing agreement for therapeutic antibody candidates generated by Genovac in collaboration with a leading research university. Genovac receives upfront payment, development and commercial milestone payments, plus royalties on net sales of commercial products.
  • North Dakota State University (NDSU)coreStrategic or Co-development Partner · 13 March 2023Public-private research collaboration focused on discovering high-quality antibodies against RAGE receptor for therapeutic development targeting melanoma and pancreatic cancer. NDSU researchers perform preclinical evaluation while Genovac provides discovery and production capabilities.
  • ENPICOMcoreTechnology or Integration · 2 May 2022Genovac uses ENPICOM's IGX Platform for advanced data management and computational analysis in antibody discovery workflows. The partnership also includes joint development of GenovacAI Humanization service powered by ENPICOM's AIGX generative deep learning model.
  • CarterracoreTechnology or Integration · 20 April 2022Genovac acquired Carterra's LSA platform, a high-throughput antibody screening and characterization technology. The LSA platform uses high-throughput surface plasmon resonance (HT-SPR) technology and is the standard in 16 of the 20 largest pharmaceutical companies. The platform was used in discovery of COVID-19 therapeutics including bamlanivimab.
  • Berkeley LightscoreTechnology or Integration · 5 October 2021Partnership for Beacon Optofluidic System for single-cell screening. Genovac operates three Beacon instruments and became the first CRO to leverage the technology for both antibody discovery and cell line development. The technology enables screening of up to 160,000 B cells per project and has dramatically improved success rates on challenging targets.
  • 10X GenomicssupportingTechnology or IntegrationGenovac offers single B cell services using 10X Genomics Chromium X instrument combined with NGS sequencing for high-throughput screening of up to 240,000 cells per day with full-length V(D)J sequences.
  • Gator BiosupportingTechnology or IntegrationPartnership for Gator Plus biolayer interferometry (BLI) platform for binding kinetics and epitope binning as a cost-effective option for smaller antibody sets (up to 24 antibodies for kinetics, 12x12 arrays for binning).

Scale indicators5 records

Recent moves9 records

Expansion highlights6 records

Genovac competitors and assessment

Company assessment

Direct peers

  • AbCellera Biologics: Public antibody discovery CRO combining single B cell screening, AI/ML, and a technology stack similar to Genovac's Beacon-based workflow. Closest publicly traded peer in business model and target customer base.
  • Adimab: Private antibody discovery platform CRO serving pharma and biotech with proprietary yeast-based discovery. Direct competitor for outsourced antibody discovery programs targeting challenging proteins.
  • AlivaMab Discovery Services: Transgenic-animal-based antibody discovery CRO offering humanized antibody generation from OmniAb platform animals. Closest direct peer to Genovac's transgenic host species (mouse, rat, rabbit, llama) offering.
  • LakePharma (Curia): Antibody discovery and development CRO, now part of Curia, offering hybridoma, B cell cloning, and characterization services that directly overlap Genovac's discovery-to-production pipeline.
  • Distributed Bio (Charles River Laboratories): Antibody discovery CRO (now part of Charles River) with SuperHuman and AbGenesis platforms; competes head-to-head with Genovac for therapeutic antibody discovery programs at biotech and pharma clients.
  • GenScript ProBio: Biologics CDMO offering antibody discovery, cell line development, and GMP manufacturing. Comparable end-to-end biologics service portfolio with greater scale and global footprint.
  • Absolute Antibody: Specialized antibody services company offering antibody sequencing, engineering, and recombinant production. Comparable in catalog and recombinant antibody services to Genovac's catalog and production offerings.

Broad incumbents

  • Lonza Biologics: Global CDMO leader in biologics manufacturing with growing discovery services. Larger, established player with integrated discovery-through-GMP offering that competes with Genovac at the high end of the market.
  • WuXi Biologics: Largest pure-play biologics CDMO globally with integrated antibody discovery through commercial manufacturing. Sets pricing and scale benchmarks against which specialized discovery CROs like Genovac must compete.
  • Catalent Biologics: Major CDMO offering biologics development and manufacturing with GPEx cell line platforms. Notable as the prior employer of Genovac's VP Pete Leland and a comparable end-to-end biologics service provider.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Genovac social profiles

Digital presence

Genovac financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Genovac leadership team

Management profile

Number of profiles

Profiles3 records

Genovac funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Genovac M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genovac

What does Genovac do?

Genovac is a contract research organization that provides antibody discovery, production, and characterization services to biotech and pharmaceutical companies. The core offering spans a gene-to-antibody workflow using genetic immunization, single B cell screening platforms (Beacon, Genovac Nano, ChromiumX), advanced hybridoma technologies, antibody production in HEK/CHO hosts, AI-powered humanization, and high-throughput binding characterization via Carterra LSA. The company also sells catalog antibodies and operates an online plasmid DNA storefront.

Is Genovac a public or private company?

Genovac is a private company. It is classified as management employee owned and is currently operating.

When was Genovac founded?

Genovac was founded in 1999. It employs 11 to 50 people.

Where is Genovac based?

Genovac is headquartered in Fargo, United States, in the North America region.

How does Genovac make money?

Four revenue lines are on record. Contract Research Services are the primary driver. The others are catalog Antibodies, plasmid DNA Production and licensing and Royalties.

Who are Genovac's main competitors?

Direct peers on record are AbCellera Biologics, Adimab, AlivaMab Discovery Services, LakePharma (Curia), Distributed Bio (Charles River Laboratories), GenScript ProBio and Absolute Antibody. Broad incumbents are Lonza Biologics, WuXi Biologics and Catalent Biologics.

Does Genovac have an API?

No public API is recorded for Genovac.

What industry is Genovac in?

Genovac's product category is Antibody Discovery Contract Research Services. Its primary akta.pro industry code is HLAGAEAD, Genomics & Molecular Diagnostics (Trial Support). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswirePhenomeX to Participate in Upcoming Cell Biology ConferencesPhenomeX Inc., a functional cell biology company, announced it will showcase its optofluidic and proteomic technologies, including the Beacon platform, at two upcoming cell biology conferences: Discovery on Target 2023 in Boston (September 25-27) and the Annual Festival of Biologics Basel in Switzerland (October 10-12). The company will present poster sessions and lead podium presentations demonstrating the Beacon platform's capabilities for antibody discovery and functional cell screening. Customer partner Genovac, a contract research organization and super user of the Beacon technology, will also deliver a presentation at the Discovery on Target conference.ThemiddlemarketGenovac Acquires the Carterra LSA InstrumentGenovac has acquired the Carterra LSA Instrument, a technology used in the discovery process for therapeutic treatments. This acquisition highlights Genovac's continued expansion in the healthcare technology sector.GenovacGenovac Acquires the Carterra LSA® Instrument to Enable State-of-the-Art Antibody Screening and Characterization ServicesGenovac has acquired the LSA platform from Carterra, Inc. to enhance its antibody screening and characterization services at its Fargo facility. This transaction marks the 100th placement of the LSA instrument globally, which is recognized for providing results 100 times faster than traditional methods.GlobeNewswireBerkeley Lights to Showcase its Optofluidic Discovery Technology at 2021 Antibody Engineering & Therapeutics ConferenceBerkeley Lights will showcase its Beacon Optofluidic System at the Antibody Engineering & Therapeutics conference in San Diego, Dec. 12-16. The system's OPBD 4.0 workflow screens up to 100,000 plasma B cells and recovers thousands of hits. Genovac's Amelie Kutschera will present on antibody discovery against difficult targets.GlobeNewswireGenovac Purchases Third Beacon® Optofluidic System andGenovac purchased a third Berkeley Lights Beacon system to expand its cell line development capabilities, adding the Opto CLD workflow to its antibody discovery platform. The company expects start-up time for CLD workflows to be up to six months shorter than other technologies, with about 2.5 hours of touch time per week. The purchase was supported by a North Dakota Bioscience Innovation Grant.GlobeNewswireLeland Joins Genovac as Vice President of Production & CharacterizationPete Leland, a 20-year biotechnology veteran, joined Genovac Antibody Discovery as vice president of production and characterization. The role enables Genovac to provide robust antibody production and characterization services to clients. Leland previously led downstream process development at Catalent and technical operations at Aldevron.GlobeNewswireGenovac Antibody Discovery Launches in NDSU Research andGenovac Antibody Discovery launched in the U.S. after a management buyout of an Aldevron antibody unit, now headquartered in Fargo, N.D. The company, led by Brian Walters, uses genetic immunization and single-cell screening to discover antibodies for therapeutic and diagnostic markets.